Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BPMUFNASDAQ:HCMNASDAQ:MLTXNYSE:OGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPMUFBasilea Pharmaceutica$47.50$49.48$47.50▼$54.00$625.58M0.4755 shsN/AHCMHUTCHMED$15.30+4.1%$14.06$11.51▼$21.50$2.67B0.55100,269 shs105,379 shsMLTXMoonLake Immunotherapeutics$51.05+5.1%$38.74$31.42▼$58.26$3.27B1.31370,504 shs1.78 million shsOGNOrganon & Co.$9.54+1.1%$10.61$8.01▼$23.10$2.45B0.583.33 million shs3.02 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPMUFBasilea Pharmaceutica0.00%0.00%0.00%-10.09%-1.35%HCMHUTCHMED+4.08%+15.65%+1.19%-4.49%-18.96%MLTXMoonLake Immunotherapeutics+5.15%+33.74%+21.84%+28.20%+25.09%OGNOrganon & Co.+1.11%+4.15%+9.34%-35.78%-54.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/AN/AN/AN/AHCMHUTCHMED1.4528 of 5 stars2.02.00.00.02.60.01.9MLTXMoonLake Immunotherapeutics2.3173 of 5 stars3.51.00.00.03.72.50.0OGNOrganon & Co.4.9116 of 5 stars3.34.01.73.71.73.33.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPMUFBasilea Pharmaceutica 4.00Strong BuyN/AN/AHCMHUTCHMED 2.00Hold$19.0024.18% UpsideMLTXMoonLake Immunotherapeutics 3.00Buy$78.7154.19% UpsideOGNOrganon & Co. 2.50Moderate Buy$18.0088.68% UpsideCurrent Analyst Ratings BreakdownLatest BPMUF, MLTX, OGN, and HCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025MLTXMoonLake ImmunotherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$67.005/22/2025OGNOrganon & Co.BNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/19/2025MLTXMoonLake ImmunotherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$61.005/15/2025OGNOrganon & Co.Piper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $18.005/13/2025HCMHUTCHMEDHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold5/13/2025MLTXMoonLake ImmunotherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$78.00 ➝ $80.005/13/2025MLTXMoonLake ImmunotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.00 ➝ $66.005/5/2025OGNOrganon & Co.Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $10.005/2/2025OGNOrganon & Co.Evercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Inline4/30/2025MLTXMoonLake ImmunotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.00 ➝ $66.004/9/2025OGNOrganon & Co.Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$16.00 ➝ $15.00(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPMUFBasilea Pharmaceutica$175.50M3.56$1.02 per share46.75($0.94) per share-50.53HCMHUTCHMED$630.20M4.23$0.62 per share24.51$4.27 per share3.58MLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$8.15 per shareN/AOGNOrganon & Co.$6.29B0.39$3.06 per share3.12($0.27) per share-35.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPMUFBasilea Pharmaceutica$11.64MN/A0.00∞N/AN/AN/AN/A8/11/2025 (Estimated)HCMHUTCHMED$100.78MN/A0.0010.48N/AN/AN/AN/A6/18/2025 (Estimated)MLTXMoonLake Immunotherapeutics-$36.01M-$2.30N/AN/AN/AN/A-15.54%-15.09%8/6/2025 (Estimated)OGNOrganon & Co.$864M$2.882.862.550.9013.49%431.62%8.03%8/5/2025 (Estimated)Latest BPMUF, MLTX, OGN, and HCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025MLTXMoonLake Immunotherapeutics-$0.76-$0.63+$0.13-$0.63N/AN/A5/1/2025Q1 2025OGNOrganon & Co.$0.89$1.02+$0.13$0.33$1.53 billion$1.51 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.84%+25.99%2.78%N/ALatest BPMUF, MLTX, OGN, and HCM DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025OGNOrganon & Co.quarterly$0.020.8%5/12/20255/12/20256/12/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPMUFBasilea Pharmaceutica5.704.103.27HCMHUTCHMED0.072.812.68MLTXMoonLake ImmunotherapeuticsN/A25.5125.51OGNOrganon & Co.17.731.701.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPMUFBasilea PharmaceuticaN/AHCMHUTCHMED8.82%MLTXMoonLake Immunotherapeutics93.85%OGNOrganon & Co.77.43%Insider OwnershipCompanyInsider OwnershipBPMUFBasilea PharmaceuticaN/AHCMHUTCHMED3.60%MLTXMoonLake Immunotherapeutics12.02%OGNOrganon & Co.1.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBPMUFBasilea Pharmaceutica14713.17 millionN/ANot OptionableHCMHUTCHMED1,760174.32 million168.04 millionNot OptionableMLTXMoonLake Immunotherapeutics264.01 million56.22 millionOptionableOGNOrganon & Co.10,000259.96 million253.93 millionNot OptionableBPMUF, MLTX, OGN, and HCM HeadlinesRecent News About These CompaniesORGANON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGNJune 4 at 11:28 PM | investing.comLaw Offices of Frank R. Cruz Encourages Organon & Co. (OGN) Investors to Inquire About Securities Fraud Class ActionJune 4 at 11:11 PM | businesswire.comDeadline Approaching: Organon & Co. (OGN) Investors Who Lost Money Urged To Contact Law Offices of Howard G. SmithJune 4 at 11:11 PM | tmcnet.comClass Action Lawsuit Alert: Levi & Korsinsky Reminds Organon & Co. (OGN) Investors of July 22, 2025 DeadlineJune 4 at 10:45 PM | accessnewswire.comORGANON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGNJune 4 at 10:31 PM | globenewswire.comOGN LAWSUIT ALERT: Levi & Korsinsky Notifies Organon & Co. Investors – Lead Plaintiff Deadline July 22, 2025June 4 at 4:10 PM | accessnewswire.comOGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJune 4 at 4:00 PM | prnewswire.comOGN LAWSUIT: Organon & Co. Lawsuit Alleges Securities Fraud Violations - Investors Notified to Contact BFA LawJune 4 at 3:46 PM | accessnewswire.comLost Money on Organon & Co. (OGN)? Join Class Action Before July 22, 2025 - Contact Levi & KorsinskyJune 4 at 3:00 PM | accessnewswire.comINVESTOR REMINDER: Berger Montague Notifies Organon & Co. (NYSE: OGN) Investors of a Class Action Lawsuit and DeadlineJune 4 at 2:36 PM | prnewswire.comJuly 22, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against OGNJune 4 at 1:01 PM | globenewswire.comLevi & Korsinsky Urges Organon (OGN) Shareholders to Act Before Lead Plaintiff Deadline July 22, 2025June 4 at 12:40 PM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co. of Class Action Lawsuit and Upcoming Deadlines - OGNJune 4 at 12:15 PM | accessnewswire.comLost Money on Organon & Co. (OGN)? Join Class Action Before July 22, 2025 - Contact Levi & KorsinskyJune 4 at 11:25 AM | accessnewswire.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of OrganonJune 4 at 11:10 AM | prnewswire.comOrganon & Co. (OGN) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before July 22, 2025June 4 at 9:30 AM | accessnewswire.comOGN LAWSUIT NOTICE: Lose Money on Organon & Co.? BFA Law Alerts Investors that the Class Action Could Allow Investors to Recover Losses (NYSE:OGN)June 4 at 9:17 AM | globenewswire.comShareholders of Organon & Co. (OGN): Protect Your Rights Before July 22, 2025 - Contact Levi & KorsinskyJune 4 at 7:20 AM | accessnewswire.comOGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Organon & Co. Investors Have Opportunity to Lead Class Action Lawsuit!June 4 at 7:00 AM | accessnewswire.comClass Action Lawsuit Alert: Levi & Korsinsky Reminds Organon & Co. (OGN) Investors of July 22, 2025 DeadlineJune 4 at 5:45 AM | accessnewswire.comOrganon & Co. (NYSE:OGN) Short Interest UpdateJune 3 at 1:34 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookAnalysts Say Unilever Has the Leverage to Hit New HighsBy Thomas Hughes | May 15, 2025View Analysts Say Unilever Has the Leverage to Hit New HighsBPMUF, MLTX, OGN, and HCM Company DescriptionsBasilea Pharmaceutica OTCMKTS:BPMUF$47.50 0.00 (0.00%) As of 06/3/2025Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.HUTCHMED NASDAQ:HCM$15.30 +0.60 (+4.08%) As of 06/4/2025 04:00 PM EasternHUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.MoonLake Immunotherapeutics NASDAQ:MLTX$51.05 +2.50 (+5.15%) As of 06/4/2025 04:00 PM EasternMoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Organon & Co. NYSE:OGN$9.54 +0.10 (+1.06%) As of 06/4/2025 03:58 PM EasternOrganon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Robinhood Stock Keeps Giving Investors Reasons To Buy CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast Guidewire Rockets Higher: A Move Above $300 Is Probable TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Intuit's AI Boom: Stock Soaring, But Should Investors Hit Pause? Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Analog Devices' Cyclical Recovery Story Has Just Begun Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
